Therapeutic Asset Ratings

464 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sb-Fix Mucopolysaccharidosis Type 2	Sangamo Therapeutics		D (30)
SIMOLADAGENE AUTOTEMCEL LENTIVIRAL VECTOR Severe Combined Immunodeficiency, Autosomal Recessive, T Cell-Negative, B Cell-Negative, NK Cell-Negative, Due To Adenosine Deaminase Deficiency	University of California, Los Angeles		D (30)
SIMOLADAGENE AUTOTEMCEL LENTIVIRAL VECTOR Severe Combined Immunodeficiency	University of California, Los Angeles		D (30)
Elzocabtagene autoleucel vector (anti-GCC CAR) Colon Carcinoma	The Affiliated Hospital of Qingdao University	N/A	D (28)
Temferon Nonpapillary Renal Cell Carcinoma	Genenta Science	P1/2	D (26)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Refractory Merkel Cell Carcinoma	National Cancer Institute (NCI)	P2	NR (0)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Skin Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	NR (0)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Skin Basal Cell Carcinoma	National Cancer Institute (NCI)	P2	NR (0)
100 μg ncp-il-22bp mrna Cancer	West China Hospital	P1	NR (0)
Kk-Lc-1 Tcr Kita-kyushu Lung Cancer Antigen 1, Human	National Cancer Institute (NCI)	P1	NR (0)
crg003 Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset	Huashan Hospital	Early P1	NR (0)
Artegene Drug Product Severe Combined Immunodeficiency Due To DCLRE1C Deficiency	Assistance Publique - Hôpitaux de Paris	P1/2	NR (0)
Gt-Ugt1A1-Aav8-02 Crigler-Najjar Syndrome Type 1	Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare	P1/2	NR (0)
st002 NF2-Related Schwannomatosis	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	NR (0)

Showing 451 to 464 of 464 assets

PreviousPage 19 of 19Next